FinTok
developed by Fiadm s.r.o. · future of webapps
Ostatné · ALKS
nákup
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 0,25 | -0,04–0,51 | 0,65 | −62,1 % |
| budúci štvrťrok | 0,09 | -0,55–0,45 | 0,48 | −81,6 % |
| tento rok | 1,27 | 0,24–2,25 | 2,10 | −39,2 % |
| budúci rok | 1,81 | 0,71–2,43 | 1,27 | +41,8 % |
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 465,1 mil. | 394,2 mil. | +18,0 % |
| budúci štvrťrok | 472,6 mil. | 384,5 mil. | +22,9 % |
| tento rok | 1,8 mld. | 1,5 mld. | +23,6 % |
| budúci rok | 1,9 mld. | 1,8 mld. | +6,5 % |
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Gaffin David JosephOfficer | predaj | 97 652 | 03.09. |
| Hopkinson Craig COfficer | uplatnenie opcií | 122 950 | 01.09. |
| Hopkinson Craig COfficer | predaj | 422 874 | 01.09. |
| Nichols Christian ToddOfficer | predaj | 372 937 | 17.08. |
| Snyderman Nancy LynnDirector | uplatnenie opcií | 2,1 mil. | 03.08. |
| Hopkinson Craig COfficer | uplatnenie opcií | 122 404 | 03.08. |
| Snyderman Nancy LynnDirector | predaj | 2,2 mil. | 03.08. |
| Gaffin David JosephOfficer | predaj | 98 812 | 03.08. |
| Hopkinson Craig COfficer | predaj | 437 220 | 03.08. |
| Gaffin David JosephOfficer | predaj | 109 897 | 06.07. |
| Hopkinson Craig COfficer | uplatnenie opcií | 96 700 | 01.07. |
| Hopkinson Craig COfficer | predaj | 463 621 | 01.07. |
Blackrock Inc.17,43 %
Baker Bros. Advisors, LP5,97 %
Vanguard Portfolio Management LLC5,66 %
State Street Corporation5,46 %
Vanguard Capital Management LLC4,48 %
Price (T.Rowe) Associates Inc4,02 %
Renaissance Technologies, LLC3,85 %
Geode Capital Management, LLC2,67 %
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
K tomuto aktívu zatiaľ nemáme odporúčanie.
Žiadne predikcie.
Investičná banka Stifel potvrdila svoje hodnotenie akcií spoločnosti Alkermes. Dôvodom je dôvera v jej produktové portfólio a budúci vývoj. Pre investorov to signalizuje stabilný výhľad.
